Le Lézard
Classified in: Health
Subjects: TDS, FVT

ImmuncoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017


LOS ANGELES, Nov. 22, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on Stem-to-T-Cell research, announced today that Anthony Gringeri, Ph.D., President and Chief Executive Officer, Steven Swanson, Ph.D., Senior Vice President, Research, and David Fractor, Chief Financial Officer, will present at the 10th Annual LD Micro Main Event on Thursday, December 7, 2017 at 9:30 a.m. PT (12:30 p.m. ET) in Track 3. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

ImmunoCellular Therapeutics Logo. (PRNewsFoto/ImmunoCellular Therapeutics) (PRNewsFoto/IMMUNOCELLULAR THERAPEUTICS)

Management will be available for one-on-one meetings on Thursday, December 7, 2017. Investors interested in arranging a meeting with management should contact their LD Micro representative or Lytham Partners at (602) 889-9700 or [email protected].

Interested parties who wish to listen to the webcast of the ImmunoCellular LD Micro presentation should visit the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event. The webcast will contain forward-looking statements. The information provided on the webcast is accurate only at the time of the webcast, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors. To learn more about ImmunoCellular, please visit www.imuc.com.

ImmunoCellular Therapeutics, Ltd. Contact:

Jane Green
(267) 457-3734 direct
(415) 652-4819 mobile
[email protected]

Investor Relations Contact:

Lytham Partners, LLC 
Joe Dorame, Robert Blum, or Joseph Diaz
(602) 889-9700
[email protected]

 

SOURCE ImmunoCellular Therapeutics, Ltd.


These press releases may also interest you

at 13:26
Introducing: The Dr. Vidal Sheen Grant for Healthcare Students
In a bid to foster excellence and innovation in the healthcare industry, the esteemed Dr. Vidal Sheen proudly announces the launch of The Dr. Vidal Sheen Grant for Healthcare Students. With a robust focus on academic prowess, compassionate care, and...

at 13:17
Rexall Launches First Pharmacist Care Walk-In Clinic in Barrie
Rexall is proud to unveil its first Pharmacist Care Walk-In Clinic in Barrie, Ontario on Friday, April 19. Located at 353 Duckworth Street, the clinic will offer personalized care to the community while providing immediate pharmacist treatment for...

at 13:13
Hartford HealthCare makes Earth-friendly pledge of carbon neutrality by 2050
Caring for communities extends beyond life-changing work in operating rooms and physician offices. Hartford HealthCare leadership today highlighted its corporate responsibility to environmental, social and economic sustainability in announcing its...

at 13:04
CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US
Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...

at 12:30
American College of Physicians issues clinical recommendations for newer pharmacological treatments of adults with Type 2 diabetes
The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best...

at 12:10
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's...

More news about Health...


News published on and distributed by: